← Evidence library

BIB_449

KEYVIBE-010 (TIGIT inhibitor vibostolimab + pembrolizumab vs pembrolizumab alone as adjuvant therapy for resected Stage IIB–IV melanoma) — NEGATIVE Phase 3 trial, DISCONTINUED at first interim futility analysis. Pembrolizumab monotherapy CONFIRMED as sole adjuvant standard; TIGIT pathway eliminated from near-term contingency escalation options for resected melanoma. Lancet Oncology 2026, PMID 41698381. Fills a zero-coverage gap in TASK17/TASK18 contingency landscape (no prior BIB covers TIGIT-class agents in melanoma adjuvant setting). Coincides with the IO102-IO103 Phase 3 PFS-endpoint miss…

Evidence grade

A

Tier

1 (Phase 3 RCT, Lancet Oncolo

Cited by tasks

17, 18, 19a

Identifiers

DOI:10.1016/S1470-2045(25 · PMID:41698381

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_449/findings.md (research corpus). This page is a short context summary — not individualised medical advice.